{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:33:01Z","timestamp":1793039581449,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1136\/ijgc-2024-005313","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T01:15:31Z","timestamp":1713921331000},"page":"906-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0278-1202","authenticated-orcid":false,"given":"Cristina","family":"Taliento","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Morciano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Nero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Froyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2424-2691","authenticated-orcid":false,"given":"Giuseppe","family":"Vizzielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-9464","authenticated-orcid":false,"given":"Matteo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Salvioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Tormen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fiorica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Scutiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-1063","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantaleo","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Pinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005313_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040650","article-title":"Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements","volume":"11","author":"Akter","year":"2022","journal-title":"Cells"},{"key":"10.1136\/ijgc-2024-005313_bb0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1515\/cclm-2017-0019","article-title":"Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA","volume":"56","author":"Giannopoulou","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1136\/ijgc-2024-005313_bb0020","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.18632\/oncotarget.7459","article-title":"Drug resistance in cancer: molecular evolution and compensatory proliferation","volume":"7","author":"Friedman","year":"2016","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2024-005313_bb0025","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.annonc.2020.05.019","article-title":"Prognostic gene expression signature for high-grade serous ovarian cancer","volume":"31","author":"Millstein","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0030","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.21037\/gs-20-544","article-title":"Role of biomarkers for early detection of ovarian cancer recurrence","volume":"9","author":"Giampaolino","year":"2020","journal-title":"Gland Surg"},{"key":"10.1136\/ijgc-2024-005313_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2022.09.004","article-title":"Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer","volume":"46","author":"Chao","year":"2023","journal-title":"Biomed J"},{"key":"10.1136\/ijgc-2024-005313_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.946257","article-title":"Whole-genome\/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial","volume":"12","author":"Sabatier","year":"2022","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0045","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1002\/1878-0261.13108","article-title":"Brca1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer","volume":"15","author":"Elazezy","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071766","article-title":"Prognostic impact of circulating methylated Homeobox A9 DNA in patients undergoing treatment for recurrent ovarian cancer","volume":"14","author":"Faaborg","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2024-005313_bb0055","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.tranon.2019.05.015","article-title":"Circulating mitochondrial DNA is linked to progression and prognosis of epithelial ovarian cancer","volume":"12","author":"Meng","year":"2019","journal-title":"Transl Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0060","article-title":"Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than Ca125","volume":"38","author":"Minato","year":"2021","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2024-005313_bb0065","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.18632\/oncotarget.14064","article-title":"Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis","volume":"8","author":"Gao","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2024-005313_bb0070","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ajog.2005.01.054","article-title":"Tumor-specific P53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer","volume":"193","author":"Swisher","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2024-005313_bb0075","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2021.03.006","article-title":"Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival","volume":"149","author":"Jakobsen","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005313_bb0080","article-title":"Publisher correction: Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration","volume":"8","author":"Nakabayashi","year":"2018","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2024-005313_bb0085","doi-asserted-by":"crossref","first-page":"21429","DOI":"10.18632\/oncotarget.15249","article-title":"RASSF1A promoter methylation in high-grade serous ovarian cancer: a direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA","volume":"8","author":"Giannopoulou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2024-005313_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-325","article-title":"LOH at 6Q and 10Q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival","volume":"12","author":"Kuhlmann","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2024-005313_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-018-0459-z","article-title":"Prognostic value of various subtypes of extracellular DNA in ovarian cancer patients","volume":"11","author":"Kalavska","year":"2018","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2024-005313_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010004","article-title":"Prognostic significance of SLFN11 methylation in plasma cell-free DNA in advanced high-grade serous ovarian cancer","volume":"14","author":"Tserpeli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2024-005313_bb0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2019.11.012","article-title":"Circulating HOXA9-methylated tumour DNA: a novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer","volume":"125","author":"Rusan","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005313_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145754","article-title":"Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers","volume":"10","author":"Pereira","year":"2015","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2024-005313_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PLoS Med"},{"key":"10.1136\/ijgc-2024-005313_bb0120","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-023-00533-1","article-title":"Circulating tumor DNA from ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients","volume":"11","author":"Kfoury","year":"2023","journal-title":"Biomark Res"},{"key":"10.1136\/ijgc-2024-005313_bb0125","first-page":"1219","article-title":"Evaluation of circulating tumor DNA in patients with ovarian cancer harboring somatic PIK3CA or KRAS mutations","volume":"52","author":"Ogasawara","year":"2020","journal-title":"Cancer Res Treat"},{"key":"10.1136\/ijgc-2024-005313_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113382","article-title":"Comprehensive gene mutation profiling of circulating tumor DNA in ovarian cancer: its pathological and prognostic impact","volume":"12","author":"Noguchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2024-005313_bb0135","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1016\/j.ejca.2014.06.022","article-title":"Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab","volume":"50","author":"Steffensen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005313_bb0140","article-title":"Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer","author":"Dobilas","year":"2022","journal-title":"In Review"},{"key":"10.1136\/ijgc-2024-005313_bb0145","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/S0090-8258(22)01348-8","article-title":"Efficacy, prognostic value of circulating tumor DNA (ctDNA) in ovarian cancer patients","volume":"166 (Suppl 1)","author":"Heo","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0150","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2022.09.004","article-title":"Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer","volume":"167","author":"Hou","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0155","first-page":"3467","article-title":"Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer","volume":"32","author":"No","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2024-005313_bb0160","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e32","article-title":"Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma","volume":"30","author":"Kim","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0165","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1136\/ijgc-2024-005313_bb0170","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","article-title":"Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2024-005313_bb0175","article-title":"TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial","volume":"29","author":"Vanderstichele","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005313_bb0180","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.phrs.2019.01.017","article-title":"Delta tocotrienol in recurrent ovarian cancer. A phase II trial","volume":"141","author":"Thomsen","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1136\/ijgc-2024-005313_bb0185","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1200\/JCO.2018.36.15_suppl.5540","article-title":"Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients","volume":"36","author":"Steffensen","year":"2018","journal-title":"JCO"},{"key":"10.1136\/ijgc-2024-005313_bb0190","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2024-005313_bb0195","author":"Wells","year":"2023","journal-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses"},{"key":"10.1136\/ijgc-2024-005313_bb0200","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/ijgc-00009577-200405000-00006","article-title":"Detection of p53 mutations in the plasma DNA of patients with ovarian cancer","volume":"14","author":"Otsuka","year":"2004","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005313_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153697","article-title":"Targeted mutational analysis of circulating tumor DNA to decipher temporal heterogeneity of high-grade serous ovarian cancer","volume":"14","author":"Paracchini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2024-005313_bb0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/1878-0261.12791","article-title":"Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients","volume":"15","author":"Charo","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47030-w","article-title":"Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using cancer personalized profiling by deep sequencing","volume":"9","author":"Iwahashi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2024-005313_bb0220","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdq584","article-title":"Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers","volume":"22","author":"Dobrzycka","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005313_bb0225","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/ijc.25602","article-title":"Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients","volume":"128","author":"Wimberger","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2024-005313_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1136\/ijgc-2024-005313_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262770","article-title":"Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer","volume":"17","author":"Heitz","year":"2022","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2024-005313_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","author":"Sausen","year":"2015","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2024-005313_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review","volume":"12","author":"Charkhchi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2024-005313_bb0250","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","article-title":"Life and death of circulating cell-free DNA","volume":"20","author":"Kustanovich","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"10.1136\/ijgc-2024-005313_bb0255","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/jnci\/djr282","article-title":"Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer","volume":"103","author":"Lee","year":"2011","journal-title":"J Natl Cancer Inst"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24014221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:30:19Z","timestamp":1753234219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24014221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1048891X24014221"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005313","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating tumor DNA as a biomarker for predicting progression-free survival and overall survival in patients with epithelial ovarian cancer: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}